MedImmune
Founded
1987
1987
Patents
94
94
Clinical Trials
274
274
Technologies
Antisense OligonucleotidesMedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular, Renal and Metabolic Diseases, and Infection and Vaccines.
Get access to BPT Crunch to view additional information about this company